Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Issues with biotechnology products in toxicologic pathology

T G Terrell1, J D Green

  • 1Department of Pathology, Genentech, Inc., South San Francisco, California 94080.

Toxicologic Pathology
|March 1, 1994
PubMed
Summary

Preclinical safety evaluation for biotechnology drugs requires new approaches beyond standard tests. Designing studies for specific scientific questions and understanding mechanisms is crucial for human risk assessment.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Assembly of the Hatching Envelope Around the Eggs of Trachypenaeus similis and Sicyonia ingentis in a Low Sodium Environment.

The Biological bulletin·2018
Same author

Abnormal Sea Urchin Fertilization Envelope Assembly in Low Sodium Seawater.

The Biological bulletin·2018
Same author

Oxidase Activity Associated with the Elevation of the Penaeoid Shrimp Hatching Envelope.

The Biological bulletin·2017
Same author

Morphological Evidence for a Chitin-Like Glycoprotein in Penaeid Hatching Envelopes.

The Biological bulletin·2017
Same author

Feeding and respiration in the New Zealand copepod Calamoecia lucasi brady.

Oecologia·2017
Same author

Longitudinal associations between post-traumatic stress disorder and metabolic syndrome severity.

Psychological medicine·2016

Area of Science:

  • Biotechnology
  • Drug Development
  • Toxicology

Background:

  • The biotechnology industry and recombinant DNA technology have introduced novel therapeutic products.
  • Traditional safety evaluation methods for small molecules are often inadequate for these complex biologics.
  • Products include hormones, growth factors, cytokines, monoclonal antibodies, vaccines, blood products, antisense, and gene therapy.

Purpose of the Study:

  • To highlight the limitations of standard preclinical safety tests for biotechnology-derived drugs.
  • To emphasize the need for tailored study designs and risk assessment strategies.
  • To guide the development of appropriate safety evaluation approaches for novel therapeutics.

Main Methods:

  • Critically evaluating the applicability of conventional safety tests.
  • Analyzing the unique challenges posed by biologics like hormones, growth factors, and gene therapies.
  • Considering species specificity, immunological responses, and dose relevance in study design.

Main Results:

  • Standard safety tests are often inappropriate or of limited value for biotechnology products.
  • Specific scientific questions, rather than regulatory compliance, should drive study design.
  • Understanding the pathogenic mechanisms of toxicological findings is essential for clinical relevance.

Conclusions:

  • Preclinical safety evaluation for biotechnology drugs necessitates a departure from traditional methods.
  • Tailored study designs focusing on biological activity, species specificity, and immunological responses are critical.
  • Defining the pathogenic mechanisms of observed effects is key to accurate human risk assessment.

Related Experiment Videos